Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.

Xu C, Zhang Y, Rolfe PA, Hernández VM, Guzman W, Kradjian G, Marelli B, Qin G, Qi J, Wang H, Yu H, Tighe R, Lo KM, English JM, Radvanyi L, Lan Y.

Clin Cancer Res. 2017 Oct 1;23(19):5869-5880. doi: 10.1158/1078-0432.CCR-17-0483. Epub 2017 Jul 5.

PMID:
28679778
2.

Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors.

Awad MM, Jones RE, Liu H, Lizotte PH, Ivanova EV, Kulkarni M, Herter-Sprie GS, Liao X, Santos AA, Bittinger MA, Keogh L, Koyama S, Almonte C, English JM, Barlow J, Richards WG, Barbie DA, Bass AJ, Rodig SJ, Hodi FS, Wucherpfennig KW, Jänne PA, Sholl LM, Hammerman PS, Wong KK, Bueno R.

Cancer Immunol Res. 2016 Dec;4(12):1038-1048. Epub 2016 Nov 14.

3.

Multiparametric profiling of non-small-cell lung cancers reveals distinct immunophenotypes.

Lizotte PH, Ivanova EV, Awad MM, Jones RE, Keogh L, Liu H, Dries R, Almonte C, Herter-Sprie GS, Santos A, Feeney NB, Paweletz CP, Kulkarni MM, Bass AJ, Rustgi AK, Yuan GC, Kufe DW, Jänne PA, Hammerman PS, Sholl LM, Hodi FS, Richards WG, Bueno R, English JM, Bittinger MA, Wong KK.

JCI Insight. 2016 Sep 8;1(14):e89014.

4.

Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment.

Lizotte PH, Jones RE, Keogh L, Ivanova E, Liu H, Awad MM, Hammerman PS, Gill RR, Richards WG, Barbie DA, Bass AJ, Bueno R, English JM, Bittinger M, Wong KK.

Sci Rep. 2016 Aug 19;6:31745. doi: 10.1038/srep31745.

5.

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.

Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English JM, Lim LP, Jänne PA, Oxnard GR.

Clin Cancer Res. 2016 Feb 15;22(4):915-22. doi: 10.1158/1078-0432.CCR-15-1627-T. Epub 2015 Oct 12.

6.

Evaluations of tropospheric aerosol properties simulated by the community earth system model with a sectional aerosol microphysics scheme.

Yu P, Toon OB, Bardeen CG, Mills MJ, Fan T, English JM, Neely RR.

J Adv Model Earth Syst. 2015 Jun;7(2):865-914. Epub 2015 Jun 19.

7.

Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.

Deng Y, Shipps GW Jr, Cooper A, English JM, Annis DA, Carr D, Nan Y, Wang T, Zhu HY, Chuang CC, Dayananth P, Hruza AW, Xiao L, Jin W, Kirschmeier P, Windsor WT, Samatar AA.

J Med Chem. 2014 Nov 13;57(21):8817-26. doi: 10.1021/jm500847m. Epub 2014 Oct 22.

PMID:
25313996
8.

Protein kinase inhibitors: breakthrough medicines and the next generation.

Sawyer TK, Wu JC, Sawyer JR, English JM.

Expert Opin Investig Drugs. 2013 Jun;22(6):675-8. doi: 10.1517/13543784.2013.804509.

PMID:
23705633
9.

Enhanced selectivity profile of pyrazole-urea based DFG-out p38alpha inhibitors.

Liu H, Kuhn C, Feru F, Jacques SL, Deshmukh GD, Ye P, Rennie GR, Johnson T, Kazmirski S, Low S, Coli R, Ding YH, Cheng AC, Tecle H, English JM, Stanton R, Wu JC.

Bioorg Med Chem Lett. 2010 Aug 15;20(16):4885-91. doi: 10.1016/j.bmcl.2010.06.073. Epub 2010 Jun 17.

PMID:
20620059
10.

Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance.

DiNitto JP, Deshmukh GD, Zhang Y, Jacques SL, Coli R, Worrall JW, Diehl W, English JM, Wu JC.

J Biochem. 2010 Apr;147(4):601-9. doi: 10.1093/jb/mvq015. Epub 2010 Feb 10.

PMID:
20147452
11.

The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.

Tecle H, Feru F, Liu H, Kuhn C, Rennie G, Morris M, Shao J, Cheng AC, Gikunju D, Miret J, Coli R, Xi SH, Clugston SL, Low S, Kazmirski S, Ding YH, Cao Q, Johnson TL, Deshmukh GD, DiNitto JP, Wu JC, English JM.

Chem Biol Drug Des. 2009 Dec;74(6):547-59. doi: 10.1111/j.1747-0285.2009.00884.x. Epub 2009 Oct 20.

PMID:
19843080
12.

KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.

Gajiwala KS, Wu JC, Christensen J, Deshmukh GD, Diehl W, DiNitto JP, English JM, Greig MJ, He YA, Jacques SL, Lunney EA, McTigue M, Molina D, Quenzer T, Wells PA, Yu X, Zhang Y, Zou A, Emmett MR, Marshall AG, Zhang HM, Demetri GD.

Proc Natl Acad Sci U S A. 2009 Feb 3;106(5):1542-7. doi: 10.1073/pnas.0812413106. Epub 2009 Jan 21.

13.

WNK1 is a novel regulator of Munc18c-syntaxin 4 complex formation in soluble NSF attachment protein receptor (SNARE)-mediated vesicle exocytosis.

Oh E, Heise CJ, English JM, Cobb MH, Thurmond DC.

J Biol Chem. 2007 Nov 9;282(45):32613-22. Epub 2007 Sep 11.

14.

Mechanisms of drug inhibition of signalling molecules.

Sebolt-Leopold JS, English JM.

Nature. 2006 May 25;441(7092):457-62. Review.

PMID:
16724058
15.

WNK1 activates SGK1 to regulate the epithelial sodium channel.

Xu BE, Stippec S, Chu PY, Lazrak A, Li XJ, Lee BH, English JM, Ortega B, Huang CL, Cobb MH.

Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10315-20. Epub 2005 Jul 8.

16.

Analysis of the ERK1,2 transcriptome in mammary epithelial cells.

Grill C, Gheyas F, Dayananth P, Jin W, Ding W, Qiu P, Wang L, Doll RJ, English JM.

Biochem J. 2004 Aug 1;381(Pt 3):635-44.

17.

Entry one: striving for best practice in professional assessment.

English JM, Mykyta L.

Aust Health Rev. 2002;25(2):129-35.

PMID:
12046140
18.

Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.

Brassard DL, English JM, Malkowski M, Kirschmeier P, Nagabhushan TL, Bishop WR.

Exp Cell Res. 2002 Feb 15;273(2):138-46.

PMID:
11822869
19.

Pharmacological inhibitors of MAPK pathways.

English JM, Cobb MH.

Trends Pharmacol Sci. 2002 Jan;23(1):40-5. Review.

PMID:
11804650
20.

ERK5 and ERK2 cooperate to regulate NF-kappaB and cell transformation.

Pearson G, English JM, White MA, Cobb MH.

J Biol Chem. 2001 Mar 16;276(11):7927-31. Epub 2000 Dec 15.

21.

WNK1, a novel mammalian serine/threonine protein kinase lacking the catalytic lysine in subdomain II.

Xu B, English JM, Wilsbacher JL, Stippec S, Goldsmith EJ, Cobb MH.

J Biol Chem. 2000 Jun 2;275(22):16795-801.

22.

Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control.

English JM, Pearson G, Hockenberry T, Shivakumar L, White MA, Cobb MH.

J Biol Chem. 1999 Oct 29;274(44):31588-92.

23.
24.

Cloning of rat MEK kinase 1 cDNA reveals an endogenous membrane-associated 195-kDa protein with a large regulatory domain.

Xu S, Robbins DJ, Christerson LB, English JM, Vanderbilt CA, Cobb MH.

Proc Natl Acad Sci U S A. 1996 May 28;93(11):5291-5.

25.

Isolation of MEK5 and differential expression of alternatively spliced forms.

English JM, Vanderbilt CA, Xu S, Marcus S, Cobb MH.

J Biol Chem. 1995 Dec 1;270(48):28897-902.

26.

Glandular excision in total glandular mastectomy and modified radical mastectomy: a comparison.

Barton FE Jr, English JM, Kingsley WB, Fietz M.

Plast Reconstr Surg. 1991 Sep;88(3):389-92; discussion 393-4.

PMID:
1871214
27.

Homeopathy.

English JM.

Practitioner. 1986 Dec;230(1422):1067-71. No abstract available.

PMID:
3313367
28.

Accidental injury in children and interrogation of families.

English JM, Sutlieff PA.

Br Med J. 1979 Oct 20;2(6196):1003. No abstract available.

29.

Infectious mononucleosis followed by Hodgkin's disease.

English JM 3rd.

Lancet. 1970 May 2;1(7653):948. No abstract available.

PMID:
4191569
30.

PROGESTATIONAL AGENTS.

ENGLISH JM.

Br Med J. 1964 Jan 4;1(5374):39-41. No abstract available.

31.

A CASE OF PROBABLE PHOSGENE POISONING.

ENGLISH JM.

Br Med J. 1964 Jan 4;1(5374):38. No abstract available.

Supplemental Content

Loading ...
Support Center